• Call(WhatsApp Us)

    +8615360806100
  • Email Us

    cherry@laeyo.com
  • 广州市花都区花山镇华辉路18号

    微观化妆品创意产业园E栋整栋

GCC Skincare Formula Exclusivity: Can a Brand Reserve a Custom Formula Across Saudi Arabia and the UAE?

Formula exclusivity in the GCC is not a product feature you buy off a price list — it is a set of written commitments, backed by documents, that have to survive the first commercial…

Category: Skincare Sourcing Guides • Author: laeyo • Published: 2026-11-11 • Views: 43

Formula exclusivity in the GCC is not a product feature you buy off a price list — it is a set of written commitments, backed by documents, that have to survive the first commercial production run. Brand owners sourcing skincare for Saudi Arabia and the UAE regularly ask whether a custom formula can be “reserved” so no competitor receives the same base, texture, or fragrance. The direct answer: yes, exclusivity is achievable, but it only becomes real when the formula carries a version-controlled ID, the territory is defined country by country, the fragrance and packaging sit inside the same agreement, and the manufacturer can produce the documentation trail that proves what was actually shipped. This guide covers the decisions to lock first, the evidence to request, and the failure modes that quietly dissolve exclusivity six months after launch.

The 60-second decision path

  • What creates the risk: skincare sold in Saudi Arabia and the UAE falls under cosmetic frameworks where a local responsible entity files the product — SFDA notification in Saudi Arabia, and for Dubai specifically the Montaji product registration route. Exclusivity in your formula does not automatically protect you commercially if the same manufacturer can reformulate a “similar” base for another brand.
  • Decide first, in this order: (1) which country is the launch market, (2) whether exclusivity is per country, per channel, or per SKU family, (3) what volume commitment you are willing to sign in exchange.
  • Fastest safe path: lock the formula ID and version, lock the fragrance code, lock the primary packaging format — then run stability and compatibility in parallel. Optimize texture and decoration later, never after the pilot run.
  • Request immediately: formula dossier with version number, fragrance/raw material letter of exclusivity, GCC-relevant stability protocol, packaging compatibility report, and the GMP/COA/SDS document pack.
  • Non-negotiable: a verbal “we won’t sell this to anyone else” is not exclusivity. Only a signed scope with markets, term, and change control is.

Informational only, not legal advice. Registration pathways and label requirements must be confirmed with your local regulatory partner for each target country.

What “exclusivity” actually means across five layers

Most exclusivity disputes trace back to a buyer and a manufacturer meaning different things by the word. Break it into five layers and assign each one its own clause and its own proof.

Exclusivity layer What it actually protects What to put in writing Evidence to request
Formula / IP The specific base, actives ratio, and processing parameters Formula ID, version number, market scope, term, ownership of the dossier Signed formula dossier + change-control clause
Fragrance & sensory The scent code and the exact sensory profile that carries your brand Fragrance house code, exclusivity window, volume trigger Fragrance house exclusivity letter naming your brand and market
Packaging & tooling Custom moulds, decoration plates, component supply Tooling ownership and who may run the mould Tooling ownership declaration + component vendor confirmation
Territory & channel Where and through whom the product may be sold Country list, channel list (retail, salon, e-commerce, gifting), carve-outs Written territory annex — Saudi Arabia and UAE listed separately
Documentation Your ability to defend the product to a regulator or a retailer Batch traceability, document handoff obligations, retention period COA, SDS, stability, micro, compatibility report, GMP certificate

Why Saudi Arabia and the UAE cannot share one exclusivity plan

The GCC is not a single market, and this matters more for exclusivity than for almost any other sourcing decision. Regulatory entry, the responsible entity, the registration system, and the commercial channel structure differ enough that a single “GCC exclusive” clause usually ends up meaning nothing in practice.

  • Saudi Arabia: the product must be notified through the SFDA cosmetic framework, with a Saudi-based importer or notifier carrying legal responsibility for the product on market. Your exclusivity clause needs to name that entity, or the brand can re-enter under a different notifier.
  • UAE — Dubai: products sold in Dubai typically go through Dubai Municipality requirements and the Montaji consumer product registration route. Registration in Dubai does not automatically cover the other emirates or the rest of the GCC.
  • Everywhere else: other GCC markets and emirates must be verified individually at project kickoff. Treat any “Middle East certificate” or “worldwide compliant” phrasing as a red flag.
  • Commercial consequence: if your exclusivity annex lists “GCC” as one line, you have no defined remedy when the same formula appears in Riyadh under a different notifier. List Saudi Arabia, the UAE, and any additional market as separate, named territories.

Decision tree: which exclusivity route fits your project

  • Start here — launching in one country first? → Sign a country-scoped exclusivity with a defined term and a volume commitment. Add territories later via a written amendment.
  • Launching in Saudi Arabia and the UAE simultaneously? → Two territory entries, two responsible entities named, one shared formula ID. Do not merge into a single clause.
  • Using a stock/base formula with your own fragrance and decoration? → Exclusivity realistically covers the fragrance code, decoration, and packaging — not the base. Say so in the contract instead of arguing later.
  • Fully custom formula with novel actives? → Full formula exclusivity is defensible, but expect a volume or term commitment in exchange.
  • Small first order (pilot or one container)? → Time-limited exclusivity (e.g., a defined window tied to reorder volume) is more realistic than perpetual exclusivity.
  • Distributor asks for exclusivity in their territory? → Separate your manufacturer exclusivity from your distributor exclusivity. They are two different contracts with two different remedy paths.
  • Boundary cases: claims that touch therapeutic territory, novel actives with unresolved safety data, or a formula developed jointly with a third-party lab — these need specialist regulatory and legal counsel before you sign anything.

What to ask your manufacturer (minimum evidence pack)

A) Formula control and IP

  • Request: the formula ID, version number, and revision history in writing.
    Evidence: signed formula dossier cover sheet with version and date.
    Owner: Manufacturer.
    Acceptance criteria: every sample you approve references a single named version; no unversioned samples accepted.
  • Request: a written exclusivity annex naming territories, channels, term, and volume trigger.
    Evidence: countersigned annex, with Saudi Arabia and UAE as separate line items.
    Owner: Buyer + Manufacturer.
    Acceptance criteria: no clause uses a collective term like “GCC” or “Middle East” without a country-by-country schedule attached.
  • Request: fragrance code and its exclusivity status, if the product is scented.
    Evidence: fragrance house letter confirming the code is reserved to your brand for the named markets and period.
    Owner: Manufacturer + fragrance house.
    Acceptance criteria: letter names your brand, the fragrance code, the markets, and an expiry date.

B) Testing and substantiation

  • Request: a stability protocol run under GCC-relevant conditions, not just home-market ambient.
    Evidence: stability report including elevated temperature and humidity exposure, plus freeze-thaw and cycle data where relevant.
    Owner: Lab.
    Acceptance criteria: report states the test conditions, duration, and pass/fail thresholds for pH, viscosity, color, odor, and separation.
  • Request: preservative efficacy and micro testing on the finished product in its final packaging.
    Evidence: challenge test report plus batch micro results.
    Owner: Lab.
    Acceptance criteria: testing performed on the commercial formula version, not an earlier prototype.
  • Request: packaging compatibility testing.
    Evidence: compatibility report covering viscosity drift, pump or airless dose consistency, leak testing, label adhesion, and fragrance-plastic contact.
    Owner: Packaging supplier + Lab.
    Acceptance criteria: the report tests the exact bottle, pump, and label combination you intend to ship.

C) Labeling and claims guardrails

  • Request: bilingual (Arabic/English) label artwork aligned to the approved formula version.
    Evidence: label file cross-checked against the INCI list and allergen declarations of that specific version.
    Owner: Buyer + Manufacturer.
    Acceptance criteria: zero discrepancy between artwork INCI and the formula dossier INCI.
  • Request: a claims list reviewed as cosmetic-only.
    Evidence: written claims matrix with substantiation reference per claim.
    Owner: Buyer + regulatory reviewer.
    Acceptance criteria: no therapeutic, medicinal, or treatment language appears anywhere; each claim maps to a test or published ingredient data point.

D) QA, traceability, and audit readiness

  • Request: the full batch documentation package for the pilot run.
    Evidence: batch record, COA, SDS, GMP certificate, retain-sample policy.
    Owner: Manufacturer.
    Acceptance criteria: documents reference the same formula version and the same production site as the commercial order.
  • Request: written change-control rules covering formula, fragrance, raw material supplier, and production site.
    Evidence: signed change-control clause with a notification window and buyer approval step.
    Owner: Buyer + Manufacturer.
    Acceptance criteria: any change requires written buyer approval before a batch is produced; unapproved changes constitute a breach, not a variance.

Evidence pack summary

  • Signed formula dossier with ID, version, and revision log.
  • Written exclusivity annex listing Saudi Arabia, UAE, and any other market separately.
  • Fragrance house exclusivity letter naming the code, brand, markets, and term.
  • Stability report under GCC-relevant temperature and humidity conditions.
  • Preservative efficacy and finished-product micro report.
  • Packaging compatibility report for the exact bottle, pump, and label combination.
  • Bilingual label artwork cross-checked against the approved INCI list.
  • Claims matrix with substantiation reference per claim.
  • Batch record, COA, SDS, and GMP certificate for the pilot batch.
  • Change-control clause with notification window and approval step.
  • Named local notifier for Saudi Arabia and named registration holder for the UAE.

Timeline: two realistic paths

Registration and testing are the two dependency chains that decide your launch date. Everything else can be compressed; these two cannot be compressed arbitrarily.

Phase Buyer action Manufacturer action Evidence output
1. Scope lock Confirm launch countries, channel, and exclusivity definition Issue formula ID and exclusivity annex draft Signed scope document
2. Formula + fragrance lock Approve golden sample; sign off sensory profile Reserve fragrance code; finalize formula version Fragrance exclusivity letter, approved formula dossier
3. Packaging lock Approve final bottle, pump, and decoration Order components; confirm tooling ownership Component sign-off, tooling declaration
4. Testing Confirm test protocol covers GCC conditions Run stability, micro, compatibility Stability, micro, and compatibility reports
5. Label & claims review Submit artwork and claims matrix to local reviewer Cross-check INCI and warnings Approved bilingual artwork
6. Pilot run Approve pilot batch; retain golden sample Produce pilot batch; compile batch record Batch record, COA, retain sample
7. Documentation handoff Confirm local notifier / registration holder is named Deliver full document pack Complete regulatory and QA document set

Fastest safe path: compress phases 1–2 into a single review cycle by using one base formula with a limited fragrance and decoration variation. Testing and label review still run in full — those are the two phases that generate rework if rushed.

Standard path: run phases sequentially with a second stability checkpoint after packaging lock. Slower, but it is the version that survives a retailer audit or a formulation challenge two years later.

Common failure modes

1. “Exclusive” turns out to be a verbal promise

  • Symptom: a near-identical product appears under another brand in the same market within a year.
  • Root cause: exclusivity was agreed in conversation, never in a signed annex with territories, term, and volume.
  • Prevention: make the annex a condition of the purchase order, not a follow-up email.
  • What to request from factory (Evidence): countersigned exclusivity annex with country-by-country schedule and a named remedy for breach.

2. Packaging compatibility failure

  • Symptom: leaks in transit, inconsistent pump dose, label lifting, or a texture that thins out after two months in a hot warehouse.
  • Root cause: the formula was validated in a lab jar, while the commercial pack was a different airless system; compatibility was never tested as a combination.
  • Prevention: lock packaging before stability testing and test the exact component set, including decoration.
  • What to request from factory (Evidence): compatibility report covering viscosity drift, leak testing, pump dose consistency, label adhesion, and fragrance-plastic contact under elevated temperature.

3. Documentation failure

  • Symptom: the retailer or notifier rejects the file set; INCI on the artwork does not match the formula on the COA.
  • Root cause: documents were compiled from different formula versions, or the INCI list was updated after artwork was released.
  • Prevention: freeze the formula version before artwork release and tie every document to that version number.
  • What to request from factory (Evidence): a document pack where COA, SDS, stability report, micro report, and label file all cite the same formula version.

4. Stability tested only in the manufacturing country

  • Symptom: product performs well in the factory’s ambient conditions but separates or discolors after GCC summer storage and transport.
  • Root cause: the stability protocol never modelled the destination climate or the shipping chain.
  • Prevention: specify elevated temperature and humidity conditions at the protocol stage, not after the first complaint.
  • What to request from factory (Evidence): stability report stating test conditions, duration, and pass/fail criteria for pH, viscosity, color, odor, and separation.

5. Claims drift after approval

  • Symptom: marketing copy on the listing or the carton starts describing treatment, repair of a condition, or a medicinal benefit.
  • Root cause: claims were approved once for the label, then rewritten by a separate marketing team with no gatekeeper.
  • Prevention: extend the claims matrix to e-commerce copy, influencer briefs, and secondary packaging.
  • What to request from factory (Evidence): written claims matrix with a substantiation reference per claim and a defined approval step for any new wording.

6. Registration scope error

  • Symptom: the product is registered in one emirate and assumed to be clear across the GCC.
  • Root cause: a single-market registration was treated as regional clearance.
  • Prevention: list every target market as a separate line in both the regulatory plan and the exclusivity annex.
  • What to request from factory (Evidence): a written statement of which registration system applies to which market, plus the named local notifier or registration holder per country.

7. Silent raw material substitution

  • Symptom: batch two feels different from batch one; the sensory profile shifts and consumers notice.
  • Root cause: a raw material supplier changed or the manufacturer substituted an equivalent grade without notification.
  • Prevention: change-control clauses that cover supplier changes, not just formula changes.
  • What to request from factory (Evidence): supplier list per raw material with substitution status, plus a signed change-control clause with a notification window.

8. Volume commitment mismatch

  • Symptom: exclusivity lapses after the pilot because the volume trigger was never defined.
  • Root cause: the contract promised exclusivity without stating what keeps it alive.
  • Prevention: tie exclusivity to a rolling twelve-month volume or a minimum annual commitment you can realistically meet.
  • What to request from factory (Evidence): written clause setting the volume or term trigger, the review date, and what happens if the trigger is missed.

Do NOT cut: red lines

  • Do not cut packaging compatibility testing to save a few weeks. A leak or pump failure at retail costs more than the entire test cycle.
  • Do not cut finished-product stability and micro testing in favor of ingredient-level data. Regulators and retailers ask about the finished product in its final pack.
  • Do not approve artwork before the formula version is frozen. The INCI mismatch is the single most common documentation failure.
  • Do not accept a collective territory term (“GCC,” “Middle East,” “worldwide”) in place of a named country schedule.
  • Do not accept therapeutic or medicinal claims on a cosmetic product, in any language, on any channel.
  • Do not accept tooling or formula ownership as a verbal understanding. If it is not written and signed, you do not own it.

Copy-paste checklist for your manufacturer

Share target countries (Saudi Arabia / UAE / other) and launch date before formula work starts.
Confirm whether exclusivity is required per country, per channel, or per SKU family.
Request the formula ID and version number in writing before approving any sample.
Attach a written definition of exclusive: markets, channels, term, and volume commitment.
Ask which fragrance house holds the scent and whether the code can be reserved to our brand.
Confirm raw material single-source risk and any pending substitution.
Lock the primary packaging format, pump or airless type, and decoration before stability testing.
Test stability under GCC-relevant temperature and humidity, not only factory ambient.
Test packaging compatibility: viscosity drift, leak, pump dose, label adhesion, fragrance-plastic contact.
Confirm preservative efficacy and micro testing are run on the finished product in final packaging.
Provide bilingual (Arabic/English) label artwork for review before print.
Verify INCI list, allergen declarations, and warnings match the approved formula version.
Confirm the claims list is cosmetic-only, with no therapeutic or medicinal wording.
Name the local notifier or importer for Saudi Arabia and the registration holder for the UAE.
Confirm which registration system applies per market and do not assume one market covers another.
Request the full document pack: COA, SDS, stability, micro, compatibility report, GMP certificate.
Review the pilot batch record and retain-sample policy.
Define the change-control clause covering formula, fragrance, supplier, and production site.
Define what happens on contract end: formula ownership, tooling ownership, remaining stock.
Approve the golden sample and store it with a signed reference sheet.
Schedule a documentation handoff review before the first commercial batch ships.

FAQ

Can one exclusivity clause cover both Saudi Arabia and the UAE?

It can be drafted that way, but it is usually a mistake. The two markets have different regulatory entry routes and different responsible entities, so a combined clause gives you no clear remedy if the formula appears in one market under a different notifier. List each country as a separate territory with its own named entity.

Is formula exclusivity legally enforceable?

Enforceability depends on the contract, the jurisdiction, and how specifically the scope is written. A clause that names the formula version, the fragrance code, the countries, the channels, the term, and the volume trigger is far more defensible than a general promise of “exclusivity.” Have your legal counsel review the drafting — this article is informational only.

Can I get exclusivity on a stock base formula?

Realistically, no. On a stock base, exclusivity usually applies to the fragrance, the decoration, and the packaging combination rather than the base itself. If base-level exclusivity is essential to your positioning, budget for a custom development and expect a volume or term commitment in return.

What is the single most important document to request first?

The version-controlled formula dossier. Everything downstream — stability, micro, compatibility, artwork, COA, and the exclusivity annex itself — references that version number. If the version is not fixed in writing, every other document can drift.

How long does a custom skincare development take if I need GCC-ready documentation?

Scope lock, formula and fragrance approval, packaging lock, stability and compatibility testing, label review, pilot run, and document handoff each carry their own lead time, and testing and label review cannot be meaningfully compressed. A pilot using a proven base with limited variation moves fastest; a fully custom formula with novel actives needs the full sequence plus a second stability checkpoint.

Next step

If you are planning a skincare launch in Saudi Arabia, the UAE, or both, the fastest way to get an accurate answer on formula exclusivity is to send the brief with the launch country, SKU count, format, positioning, packaging direction, and target timeline. That single email is usually enough to return a scoped proposal with the exclusivity structure, testing plan, and documentation list attached.

Request a Quote

Hi, I'm your LAEYO representative, hope you like this blog post.

With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.

  • Our team will answer your inquiries within 8 hours.
  • Your information will be kept strictly confidential.

Request received

Thanks — we’ve received your request. Our team will follow up shortly. we typically reply within 8 hours (often sooner).